Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies ...
Pathfinder Cell Therapy reported revenue of $0 for fiscal year 2014, down 100.0% from fiscal year 2013, and net income of -$1.39 million. In Q3 2015 (the quarter ended September 30, 2015) revenue was $0. Its largest business segment, Russian Federation, brought in 90% of segment revenue in fiscal year 2013; Mts Czech Republic was the largest region with 37%.
Figures from company filings; latest fiscal year ended December 31, 2014.
No profile data available.